The combination medication is used for the treatment of Parkinson's disease.
Cadila Healthcare in a regulatory filing announced that Zydus Cadila has received a tentative approval from the USFDA to market Carbidopa and Levodopa Extended-Release Capsules.The combination medication is indicated for the treatment of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, and difficulty moving).
The company further said that capsules will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
Zydus Cadila group now has 282 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare were trading 0.97% lower at Rs 250.35 on BSE.
Cadila Healthcare is a pharmaceutical company based in India.
Powered by Capital Market - Live News